Literature DB >> 3935709

The influence of thyroid disorders on the dopaminergic regulation of prolactin, thyrotropin and growth hormone.

P C Eskildsen, C B Kirkegaard.   

Abstract

In order to clarify if hyper- and hypothyroidism change by feed-back mechanisms the dopaminergic controlled release of PRL, TSH and GH, the serum values of these hormones were measured before and following iv administration of 5 mg metoclopramide in 10 hyperthyroid, 11 euthyroid and 10 primary hypothyroid age-matched females, all consecutively investigated. The secretion pattern, as well as the quantitated response (area under the curve - AUC) of PRL were identical for the three groups, and uninfluenced by thyroid status. By contrast the TSH responses (AUC) were significantly and positively correlated to the basal TSH, suggesting that the effect of metoclopramide was dependent on the secretory capacity of the thyrotropic cells. The serum GH level was found to decrease in all three groups following metoclopramide, probably due to the inhibition of release. Stimulation of the same subjects with 200 micrograms TRH iv resulted in response curves of serum PRL and TSH, which were significantly and positively correlated to the basal serum TSH. The serum values of GH increased following TRH in the hypothyroid group, while the values of the hyperthyroid were depressed and unchanged. The present results suggest that the dopaminergic tonus on PRL, TSH and GH secretion is unaffected by thyroid feed-back mechanisms. The TRH-induced release of each of the three hormones is, however, dependent on thyroid status.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935709     DOI: 10.1007/BF03348530

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  Plasma prolactin and thyrotropin and the response to thyrotropin-releasing factor in children with primary and hypothalamic hypothyroidism.

Authors:  S N Suter; S L Kaplan; M L Aubert; M M Grumbach
Journal:  J Clin Endocrinol Metab       Date:  1978-11       Impact factor: 5.958

2.  Twenty-four-hour prolactin profiles in normal and disease states: failure of thyroxine to modify prolactin secretion.

Authors:  W B Malarkey; P Beck
Journal:  J Clin Endocrinol Metab       Date:  1975-04       Impact factor: 5.958

Review 3.  Prolactin.

Authors:  A G Frantz
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

4.  Hypothyroidism presenting with hyperprolactinaemia.

Authors:  C G Semple; G H Beastall; G Teasdale; J A Thomson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-09

5.  The thyrotropin response to thyrotropin-releasing hormone in endogenous depression.

Authors:  C Kirkegaard
Journal:  Psychoneuroendocrinology       Date:  1981       Impact factor: 4.905

6.  Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone.

Authors:  P J Snyder; L S Jacobs; R D Utiger; W H Daughaday
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

Review 7.  Prolactin.

Authors:  M O Thorner
Journal:  Clin Endocrinol Metab       Date:  1977-03

8.  Increase in plasma growth hormone levels following thyrotropin-releasing hormone injection in children with primary hypothyroidism.

Authors:  R Collu; G Leboeuf; J Letarte; J R Ducharme
Journal:  J Clin Endocrinol Metab       Date:  1977-04       Impact factor: 5.958

9.  Prolactin response to metoclopramide in hyperthyroidism.

Authors:  J S Sawers; H A Kellett; N S Brown; J Seth; A D Toft
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

10.  On the role of dopamine receptors in the central regulation of human TSH.

Authors:  G Delitala; L Devilla; A Canessa; F D'Asta
Journal:  Acta Endocrinol (Copenh)       Date:  1981-12
View more
  2 in total

1.  Subnormal prolactin responsiveness to thyrotropin-releasing hormone (TRH) in women with primary empty sella syndrome.

Authors:  M F Celani; G Giambuzzi; M Simoni; V Montanini
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

Review 2.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.